UroGen Pharma Ltd. Stock News

UroGen Pharma's FDA approval for UGN-102 removes existential risk and validates a contrarian investment stance, driving a sharp stock price recovery. A key investment thesis now hinges on UGN-102's commercial uptake, as physician adoption versus entrenched surgical standards remains uncertain. UroGen's financial runway is limited, with high cash burn and royalty obligations, raising the likelih...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and steril...

The U.S. Food and Drug Administration has approved Urogen Pharma's drug to treat a type of bladder cancer, the regulator said on Thursday.

LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).

NEW YORK , June 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period").

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The 7 major bladder cancer markets are expected to reach $5.4 billion by 2034. Company is developing anti-CTLA4 antibody UGN-301 in a phase 1 study either alone as a monotherapy or in combination to targe...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 131...